Vaso Dynamics

This week we are introducing Dr Austin Smith, Deputy Medical Officer at Vasodynamics Ltd. Austin began his journey into oncology, after learning the finer art of flow cytometry during a Medical School summer elective and seeing the challenges that arise from within the human genome. Austin started his clinical experience as a Clinical Oncologist where he also conducted scientific research into cancer paraneoplastic syndrome. He moved ultimately into Medical Oncology, learning about both the fantastic outcomes from cancer therapeutics but also their limitations and the harsh impacts of not only the cancer but the therapies undertaken. Austin's last clinical position was that of Oncology Resident at The London Clinic where he established the UK's first Cancer Fatigue unit whilst also working as part of the core team for the start of the Devonshire Wing. He also established multiple working partnerships with large pharma. This helped patients to align lifestyle changes and focus on the elements of wellbeing often forgotten by overworked clinical teams. In industry, Austin worked alongside experts from the US National Cancer Institute, Cancer Therapy Evaluation Programme and finalized his training in Pharmaceutical Medicine. He currently sits within the Oncology Expert Group for the Faculty of Pharmaceutical Medicine. Since then, Austin has been providing support to emerging biotechs as an expert in clinical development and regulatory science and has worked at board level in several biotech companies in UK, Europe, and Australia where he provides expertise with regulatory meetings and fund-raising activities. He also enjoys providing expert training to academic units in several countries on how to develop novel projects into pharmaceuticals.

We are pleased to announce that Vasodynamics has been awarded a significant UK-Taiwan Collaborative R&D Grant from Innovate UK and Taiwan's Department of Industrial Technology, MOEA. This funding will support an international collaboration in partnership with Genenet, Anntond Ind Co Ltd, Pythia Biotech Ltd on groundbreaking R&D efforts to advance organ-on-chip technology for high-efficiency real-time monitoring in microphysiological systems. Our CEO, Ningfeng Fiona Li said: “VasoDynamics are delighted to be part of this Innovation UK Grant consortium to contribute to the innovation and development of this new groundbreaking technology. We are looking forward to taking this opportunity to participate in improving the AI-embedded toxicity screening technology to modernise and accelerate our drug discovery and validation process.”

🎉 We Did It! We Did It! We Did It! Yeah! 🎉 We proudly announce that GeneNet has been awarded a significant UK-Taiwan Collaborative R&D Grant from Innovate UK and Taiwan's 經濟部產業技術司 (Department of Industrial Technology, MOEA). This exciting funding will support our groundbreaking R&D efforts with our amazing partners 映通 (ANN TONG IND. CO., LTD.), 達運精密, 諭泰生技 (Pythia Biotech LTD.), and Vaso Dynamics to advance organ-on-chip technology for high-efficiency real-time monitoring in microphysiological systems. This milestone reflects the strength of international collaboration in driving innovation in biotech and healthcare. A huge thank you to UK in Taiwan 英國在台辦事處 for championing global R&D partnerships. We’re energized by this achievement and ready to take our innovations to the next level. Stay tuned for updates as we continue to lead in cutting-edge biotechnology. 🚀 #Biotech #Innovation #OrganOnChip #台英合作 #創新科技 #生醫

VasoDynamics is attending and presenting at the LSX Inv€$tival Showcase 2024 next Monday on the 18th November. We’re excited to take part in Europe's biggest dedicated healthcare investment week. Our CEO, Ningfeng Fiona Li, will be presenting a company showcase on the Biotech Startup stage at 11:40! Interested in our work? Come along to our presentation or send us a message to arrange a meeting. #investival

VasoDynamics is attending and exhibiting at the Head & Neck Cancer Conference 2024 Sheffield on the 6-7th November. We’re looking forward to two days of hearing from inspirational speakers, enhancing our own knowledge, making connections and sharing ideas with patients, caregivers, health professionals and companies. Interested in our work? Come and have a chat at our stand, see our poster or send us a message to arrange a meeting. #HNCCONF2024

Following the successful completion of the NG11-2 phase-1b clinical trial, the VasoDynamics team are carrying out a series of Scientific Advisory meetings with key regulatory authorities worldwide in order to develop an optimal market access strategy. Earlier this month, we completed a meeting with the Regulatory Authority in the Netherlands, the Medicines Evaluation Board (MEB), and obtained invaluable advice. We look forward to building on this progress to further clarify the development and market access roadmap that will enable us to deliver our treatments to patients as soon as possible. https://lnkd.in/eZjf-JkB

Introducing @Gary Bower, Chief Operating Officer at VasoDynamics! After getting a degree in Chemistry from Imperial College, London, Gary began his career as a R&D chemist developing new radiopharmaceuticals and providing radiolabelled agents to pharma companies for research purposes. After 8 years, Gary moved into Clinical Research during the first “biotech era” at the end of the 90s and ran a series of clinical studies including a global phase-3 clinical trial investigating the use of radiolabelled antibodies in the treatment of ovarian cancer. Subsequently Gary set up his own consultancy business providing support to small biotech companies in their preclinical and clinical development, primarily in oncology by managing clinical trials across all phases (I-IV) of development. Having worked increasingly in the area of “cancer supportive care” over the past few years, Gary joined VasoDynamics in 2021 to develop products in areas with a significant unmet medical need. He hopes the extensive experience in rapid drug development on the VasoDynamics team can deliver these treatments to patients soon.

We have reached the ‘Last Patient Last Visit’ milestone in our VDL NG11-2 Phase 1b Clinical Trial. Preparations for database lock and study close out are now well underway. Looking forward to the next stages of development of this treatment aimed at reducing the debilitating condition, Radiation-Induced Oral Mucositis in patients with Head and Neck Cancer. More information below…..

Exciting Milestone Achieved at VasoDynamics! We are thrilled to announce that the final patient visit for our NG11-2 Phase-Ib study has been successfully completed as of August 20th, 2024! This study investigates the safety and preliminary efficacy of NG11-2, a promising innovative oral topical therapy aimed at reducing Radiation-Induced Oral Mucositis (RIOM) in patients undergoing radiotherapy for head & neck cancer. With the study now in the Close-Out phase, we anticipate the completion of locking the study database in September and sharing the Clinical Study Report later this year. A huge thanks to our dedicated team and clinical sites for their hard work and support. We look forward to sharing the results of this exciting research and advancing the pivotal clinical development of NG11-2. https://lnkd.in/eNBXPA_f

The team at VasoDynamics are saddened to hear of the sudden passing of Dr Torsten Goesch last week. Torsten had been Chair of the VasoDynamics Board until recently and contributed greatly to the early development of VasoDynamics and its technology. Our thoughts are with Torsten’s family and friends at this difficult time.